Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × testosterone enanthate × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Castration Resistant Metastatic Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 52 Specimen Handling 48 enzalutamide 41 Prednisone 36 apalutamide 34 Androgen Antagonists 33 Abiraterone Acetate 32 Leuprolide 29 darolutamide 28 Radiosurgery 27 Radiotherapy 23 Pluvicto 22 Docetaxel 19 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 18 Biopsy 18 relugolix 17 abiraterone 16 Goserelin 15 Surveys and Questionnaires 14 Radiation 14 bicalutamide 13 Triptorelin Pamoate 13 X-Rays 12 prednylidene 11 deltacortene 11 cabazitaxel 11 Standard of Care 11 Gonadotropin-Releasing Hormone 11 luprolide acetate gel depot 10 Carboplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06594926 2026-04-13

WOMBAT

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡